AOD-9604: A Complete Guide to the hGH Fragment Peptide

AOD-9604 is a 16-amino-acid fragment of human growth hormone, engineered by Australian researchers to isolate the lipolytic effects of the parent molecule without affecting blood sugar or tissue growth. It has been studied for its role in fat metabolism and body composition, and is currently classified as Category 2 by the FDA.

What Is AOD-9604?

AOD-9604 stands for "Anti-Obesity Drug 9604." It is composed of 16 amino acids drawn from the lipolytic region of growth hormone, with an added tyrosine residue at the N-terminus to improve stability and pharmacokinetics.

The design goal was selectivity: preserve the fat-metabolism activity of growth hormone while leaving glucose regulation, insulin sensitivity, and tissue growth pathways unaffected.

The peptide was developed at Monash University in Melbourne in the late 1990s and early 2000s, advancing through preclinical studies into human trials.

How Does AOD-9604 Work?

Research suggests AOD-9604 acts on adipose tissue through two complementary mechanisms: stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation of new fat).

The selectivity of this action is what distinguishes it from full growth hormone. Where parent hGH affects glucose metabolism, insulin sensitivity, IGF-1 production, and tissue growth, AOD-9604 has been studied for its more focused effect on fat metabolism alone.

Some studies have explored beta-3 adrenergic receptor pathways as a potential mechanism, since these receptors regulate fat cell thermogenesis and lipolysis. The full molecular picture continues to be characterized through ongoing research.

What Is AOD-9604 Studied For?

What have researchers actually studied AOD-9604 for? Mostly metabolic stuff:

• Fat metabolism: The primary focus of AOD-9604 research has been its potential effects on adipose tissue metabolism, including the breakdown of stored fat and reduction in fat accumulation.
• Body composition: Clinical trials have explored AOD-9604's potential influence on body composition parameters, including measurements of body fat percentage, lean mass, and fat distribution patterns.
• Weight management: Some studies have investigated AOD-9604 in the context of body weight regulation and metabolic health markers in individuals with elevated body fat levels.
• Cartilage repair: Interestingly, research has also explored potential applications beyond fat metabolism. Some studies have investigated whether AOD-9604 might have beneficial effects on cartilage regeneration and joint health, though this represents a different research direction from its metabolic applications.
• Metabolic parameters: Research has examined AOD-9604's relationship to various metabolic markers, including lipid profiles and energy expenditure, while monitoring for potential effects on glucose metabolism and insulin sensitivity.

Early preclinical studies were encouraging, and several human trials produced supportive data on tolerability and metabolic effects. Subsequent research has produced mixed results across populations and study designs, and the efficacy question continues to be examined.

Regulatory Status and History

AOD-9604 has followed a varied regulatory path across jurisdictions.

United States: AOD-9604 is currently classified as Category 2 under FDA compounding guidance, meaning it is not currently available for compounding. The FDA reviews substances based on evidence, clinical need, and safety profile, and classifications can be reconsidered as new data becomes available. PeptidePrescript monitors FDA guidance daily and will notify waitlist subscribers if AOD-9604's status changes.

Australia: AOD-9604 was developed in Australia, and Australian regulators have evaluated it across multiple submissions. The TGA granted GRAS (Generally Recognized as Safe) status in 2010 for use as a food ingredient, indicating an acceptable safety profile in that context.

International: Regulatory status varies by country. Anyone interested in AOD-9604 should consult applicable local regulations and work with a licensed provider.

Ongoing research: Scientific investigation of AOD-9604 continues across multiple research groups, with new findings periodically informing the broader evidence base.

Side Effects and Safety

Safety data from clinical trials provides a useful starting picture, with continued research expected as the field develops.

General tolerability: Clinical trials have reported AOD-9604 as well-tolerated, with serious adverse events rare in published studies.

Injection site reactions: Mild, short-lived redness or discomfort at the injection site has been reported, consistent with subcutaneous peptide administration generally.

Systemic effects: Some trial participants have reported headaches, joint discomfort, or fatigue. Larger studies would help characterize the relationship between these reports and the peptide itself.

Metabolic profile: A key research finding is that AOD-9604 has not been shown to affect blood glucose or insulin sensitivity in the way that full growth hormone does, consistent with the peptide's design goal of selective lipolytic activity.

Long-term data: Most published trials have been short-term, so longer-duration studies would help characterize extended-use safety profiles.

Eligibility: Since AOD-9604 is not currently available for prescription in the U.S., it is not part of any current care plan. If status changes, candidacy would be evaluated through the standard process, with conditions such as pregnancy, breastfeeding, and concurrent medications all considered through medical evaluation.

Frequently Asked Questions

Is AOD-9604 the same as growth hormone?

No, AOD-9604 is a small fragment representing only amino acids 176-191 of the full 191-amino-acid human growth hormone molecule. While it's derived from hGH, it does not replicate all of growth hormone's effects. Research suggests AOD-9604 may retain some fat metabolism properties while lacking growth hormone's effects on glucose metabolism, IGF-1 production, and tissue growth. The two substances have very different pharmacological profiles.

Why isn't AOD-9604 available in the United States?

AOD-9604 currently holds Category 2 status under FDA compounding guidance, which means it has been nominated but not approved for use in compounding. The FDA evaluates substances for compounding based on clinical need, safety, and evidence quality. AOD-9604's current classification reflects the regulatory evaluation process. Only peptides with Category 1 status can be prescribed through compounding pharmacies in the U.S.

Has AOD-9604 been studied in humans?

Yes, AOD-9604 has been investigated in human clinical trials examining its effects on body composition, fat metabolism, and safety parameters. These studies have provided data on tolerability and metabolic effects. However, the overall body of evidence has not been sufficient for regulatory approval as a pharmaceutical medication in major jurisdictions. Published research provides valuable scientific information but should not be interpreted as validation of clinical efficacy or safety for widespread use.

Could AOD-9604 become available in the future?

The regulatory status of peptides can change based on new evidence, clinical need, or policy considerations. If additional research data or other factors lead to reevaluation, it's possible that AOD-9604's classification could be reconsidered. However, we cannot predict whether or when such changes might occur. PeptidePrescript monitors the regulatory landscape and will update our offerings if and when substances transition to Category 1 status.

What alternatives are currently available?

Several other peptides with Category 1 status are currently available through doctor prescription for various health and wellness goals. Depending on your specific interests and health profile, your doctor may recommend alternatives that are appropriate for your situation. PeptidePrescript's peptide catalog shows all currently available Category 1 options, and our doctors can help identify the right fit for your goals.